Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
Generate Biomedicines official news-release RSS · 行業原文收錄 · 來源發佈：Mon Dec 01 2025 10:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
SOLAIRIA‑1 and SOLAIRIA‑2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the promise of programmable biology SOMERVILLE, Mass., December 1, 2025— Generate:Biomedicines (“Generate”) tod
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。